Kelly Dooley

Short-Course Rifapentine for TB Prevention for All: Clinical Pharmacology Matters

National Institute of Allergy and Infectious Diseases · R37

Contact PI · $1.7M · Vanderbilt University Medical Center

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium

National Institute of Allergy and Infectious Diseases · UM1

PI · $22.2M · University of California, San Francisco

JHU TRAC: Training and Supporting the Next Generation of TB Researchers

National Institute of Allergy and Infectious Diseases · P30

Project lead · $164.3K · Johns Hopkins University

Mentoring Investigators in HIV and Tuberculosis Therapeutics Research

National Institute of Allergy and Infectious Diseases · K24

Contact PI · $789.2K · Vanderbilt University Medical Center

INSTI's For The Management of HIV-associated TB

Principal investigator · Completed · Phase 2

Centre for the AIDS Programme of Research in South Africa

Optimizing Treatment to Improve TBM Outcomes in Children

Principal investigator · Completed · Phase 1, Phase 2

Johns Hopkins University

Assessing PA-824 for Tuberculosis (the APT Trial)

Principal investigator · Completed · Phase 2

Johns Hopkins University

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

Principal investigator · Completed · Phase 1

Johns Hopkins University